These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 18258572)

  • 1. The prevalence of vitamin D deficiency and insufficiency in a hematology-oncology clinic.
    Everett PC
    Clin J Oncol Nurs; 2008 Feb; 12(1):33-5. PubMed ID: 18258572
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence of vitamin D insufficiency in Brazilian adolescents.
    Peters BS; dos Santos LC; Fisberg M; Wood RJ; Martini LA
    Ann Nutr Metab; 2009; 54(1):15-21. PubMed ID: 19194104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential therapy with tamoxifen and aromatase inhibitors in early-stage postmenopausal breast cancer: a review of the evidence.
    Litsas G
    Oncol Nurs Forum; 2008 Jul; 35(4):714-21. PubMed ID: 18591176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients.
    Blair D; Byham-Gray L; Lewis E; McCaffrey S
    J Ren Nutr; 2008 Jul; 18(4):375-82. PubMed ID: 18558303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing hematologic toxicities in the oncology patient.
    Montoya L
    J Infus Nurs; 2007; 30(3):168-72. PubMed ID: 17505218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE; Body JJ; Gralow JR; Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacotherapeutic management of osteoprosis and osteopenia.
    Alexander IM
    Nurse Pract; 2009 Jun; 34(6):30-40; quiz 41. PubMed ID: 19474629
    [No Abstract]   [Full Text] [Related]  

  • 9. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of aromatase inhibitors on bone metabolism.
    Folkestad L; Bjarnason NH; Bjerregaard JK; Brixen K
    Basic Clin Pharmacol Toxicol; 2009 Jan; 104(1):3-10. PubMed ID: 19152547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of osteoporosis associated with breast cancer treatment: the need to access to preventive treatment.
    Rozenberg S; Carly B; Liebens F; Antoine C
    Maturitas; 2009 Sep; 64(1):1-3. PubMed ID: 19709824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paricalcitol for reduction of albuminuria in diabetes.
    Delanaye P; Mariat C; Krzesinski JM; Cavalier E
    Lancet; 2011 Feb; 377(9766):635, author reply 636-7. PubMed ID: 21334526
    [No Abstract]   [Full Text] [Related]  

  • 13. Supportive care: large studies ease yoga, exercise into mainstream oncology.
    Hede K
    J Natl Cancer Inst; 2011 Jan; 103(1):11-2. PubMed ID: 21169537
    [No Abstract]   [Full Text] [Related]  

  • 14. Prevalence of secondary causes of bone loss among breast cancer patients with osteopenia and osteoporosis.
    Camacho PM; Dayal AS; Diaz JL; Nabhan FA; Agarwal M; Norton JG; Robinson PA; Albain KS
    J Clin Oncol; 2008 Nov; 26(33):5380-5. PubMed ID: 18955450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AIM Higher Initiative: new procedures implemented for assessment, information, and management of chemotherapy toxicities in community oncology clinics.
    Moore K; Johnson G; Fortner BV; Houts AC
    Clin J Oncol Nurs; 2008 Apr; 12(2):229-38. PubMed ID: 18390459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
    Kearney N; Friese C
    Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates.
    Wang-Gillam A; Miles DA; Hutchins LF
    Oncologist; 2008 Jul; 13(7):821-7. PubMed ID: 18614589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shedding light on vitamin D and integrative oncology.
    Cantor I
    Integr Cancer Ther; 2008 Jun; 7(2):81-9. PubMed ID: 18505900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial.
    Fishbane S; Chittineni H; Packman M; Dutka P; Ali N; Durie N
    Am J Kidney Dis; 2009 Oct; 54(4):647-52. PubMed ID: 19596163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paricalcitol for reduction of albuminuria in diabetes.
    Ortiz A; Sanchez Niño MD; Rojas J; Egido J
    Lancet; 2011 Feb; 377(9766):635-6, author reply 636-7. PubMed ID: 21334525
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.